Since it first appeared at the end of 2019, SARS-CoV-2, the virus that causes COVID-19, has proven adept at spreading rapidly throughout entire populations. To stop the virus in its tracks, we need to be able to quickly identify people who are infected, including those with little or nothing in the way of symptoms.
Currently, the most reliable and safest method of testing for COVID-19 is through a PCR (polymerase chain reaction) test. However, the test alone can take several hours to run, plus samples have to be sent to a laboratory, meaning most patients have to wait at least a day to get the result. Faster tests do exist but are expensive and not always reliable.
The aim of DECISION is to develop an easy-to-use, low-cost, disposable test for COVID-19 that can give reliable results, on the spot, within minutes. The idea is that it can be deployed anywhere; at drive-through testing centres, airports, physician offices, hospitals, quarantine centres, and eventually, even in people’s own homes.
DECISION’s test is based on Pulse Controlled Amplification (PCA) technology. Like a PCR test, PCA amplifies the genetic material of the virus. However, PCA is both faster and cheaper, and the device itself is portable. Ultimately, the project hopes that users will have to wait just 15 minutes to get their result.
ParticipantsShow participants on map
Universities, research organisations, public bodies, non-profit groups
- Ait Austrian Institute Of Technology GMBH, Wien, Austria
- Bundesministerium Der Verteidigung, Bonn, Germany
- Istituto Nazionale Per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura A Carattere Scientifico, Rome, Italy
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
- Gna Biosolutions GMBH, Martinsried, Germany
|Name||IHI funding in €|
|Ait Austrian Institute Of Technology GMBH||2 064 178|
|Bundesministerium Der Verteidigung||425 250|
|Gna Biosolutions GMBH||196 268|
|Istituto Nazionale Per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura A Carattere Scientifico||406 350|
|Microliquid SL (left the project)||343 053|
|Total Cost||3 435 099|